Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.

Endocrine - 1 Dec 2020

Chen Yunzhi, Yan Xuemei, Xu Xiao, Yuan Shuhua, Xu Fen, Liang Hua

Abstract excerpt

PURPOSE: GLP-1 receptor agonists, such as exenatide, have been proven to attenuate nonalcoholic fatty liver disease (NAFLD) in vivo and in vitro. However, the efficiency of exenatide had interindividual differences. PNPLA3 is a major susceptibility gene for NAFLD and its I148M polymorphism increases the risk of all disorders of the NAFLD spectrum. Whether this variant contributes to variability in exenatide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Genetic Predisposition to Disease
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Lipase

Share to Membrane Proteins

Share to Non-alcoholic Fatty Liver Disease

Source

Identifiers

PMID: 32862405
DOI: 10.1007/s12020-020-02470-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.PMID 32862405Read ↗

PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Semantic proximity Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

Function of PNPLA3 I148M-Lessons From In Vivo Studies in Humans.Semantic proximity Read ↗

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.Semantic proximity Read ↗

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variantsSemantic proximity Read ↗

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseSemantic proximity Read ↗

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Semantic proximity Read ↗

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Semantic proximity Read ↗

PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.Semantic proximity Read ↗

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.Semantic proximity Read ↗

Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.Semantic proximity Read ↗

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.